A TOOL FOR NON INVASIVE ASSESSMENT AND QUANTIFICATION OF STEATOSIS CAP™ is a measure of the ultrasound attenuation which corresponds to the decrease in amplitude of ultrasound waves as they propagate through the liver. CAP is powered by a sophisticated guidance process based on VCTE™ ensuring that: → Steatosis and stiffness are simultaneously measured in the same liver volume → Liver steatosis is calculated only if liver stiffness measurement is valid → Gain (ultrasound amplitude) → Ultrasound frequency are controlled and predefined → Area of measurement → CAP is measured at 3.5 MHz and is expressed in decibel per meter (dB/m). → CAP is measured with the M probe at depth between 25 and 65 mm for adult patients with a skin capsula distance < 2.5 cm. → CAP is measured with the XL probe at depth between 35 and 75 mm for adult patients with a skin capsula distance between 2.5 cm and 3.5 cm. CAP measurement Like for liver stiffness measurement, CAP measurement: → is non invasive → is immediate: does not lengthen the FibroScan® examination → can be performed by an operator without any ultrasound imaging skills BIBLIOGRAPHY BY ECHOSENS 1.de Ledinghen, V., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014 May;60(5):1026- 31. 2.Karlas T, et al., Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014 Mar 17;9(3):e91987. 3.Masaki K, et al., Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res. 2013 Nov;43(11):1182-9. 4.Myers, R.P, et al., Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. LiverTM International, 2012. 32(6): p.902-10. 5.de Ledinghen, V., et al. Non invasive diagnosis of liver steatosis using Controlled Attenuation Parameter (CAP™) and transient elastography. Liver Int, 2012. 32(6): p. 911-8. 6.Sasso, M., et al., Novel Controlled Attenuation Parameter (CAP) for noninvasive assessment of steatosis using FibroScan: validation in chronic hepatitis C.TM ®Journal of Viral Hepatitis, 2012. 36(1): p.73-20. 7.Sasso, M., et al., Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuatiTMon measurement for the evaluation of hepatic steatosis - Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in Medicine and Biology, 2010. 36(11): p. 1825-1835. 8.Cardoso, A.F., et al. Controlled Attenuation Parameter: a novel FibroScan-based tool to detect andq®uantify steatosis in chronic hepatitis B. in 61Annual Meeting ofst the American Association for the Study of Liver Disease. 2010. Boston, MA, USA. Our products are subject to regulatory requirements that vary from country to country and therefore may not be available for sale or distribution in all markets. This marketing material is not intended for US audience. WWW.ECHOSENS.COM ®®MTMT NE 710260 PAC - DEVRESER STHGIR LLA SNESOHCE THGIRYPOC © YNAPMOC SNESOHCE FO SKRAMEDART ERA , NACSORBIF , ,SNESOHCE - 58431 OSI - 9540